Microcurrent Stimulation to Treat Macular Degeneration
Launched by RETINA INSTITUTE OF HAWAII · Feb 11, 2013
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
This is an observational study in which data will be collected from a group of patients with retinal diseases such as Dry Macular Degeneration, RetinitisPigmentosa, and Stargardt's Disease, who have opted to receive Microcurrent Stimulation Therapy as an alternative treatment for their retinal condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to provide written consent and comply with follow up visits
- • Age 40 years or older
- • ETDRS best corrected visual acuity better than 5 letters
- • History of Dry Age Relted Macular Degeneration; Retinitis Pigmentosa; Stargardt's disease
- • No Anti-VEGF treatments for at least 3 months prior to study
- • No new antioxidant/vitamin supplementation for at least 3 months prior to study
- Exclusion Criteria:
- • History of Non-Compliance with regular medical visits
- • Significant media opacities (exclude NS 4+) that may interfere with assessing visual acuity
- • Presence of pigment epithelial tears or rips
- • Known serious allergies to fluorescein dye
- • Presence of retinal neovascularization
- • Any treatment with an investigation agent in the past 30 days
About Retina Institute Of Hawaii
The Retina Institute of Hawaii is a leading clinical research organization dedicated to advancing the understanding and treatment of retinal diseases. With a focus on innovative therapies and cutting-edge clinical trials, the institute strives to improve patient outcomes through rigorous scientific investigation and collaboration with top-tier researchers and healthcare professionals. Committed to excellence in patient care and research integrity, the Retina Institute of Hawaii plays a pivotal role in shaping the future of ophthalmology by facilitating the development of novel treatments for conditions such as age-related macular degeneration, diabetic retinopathy, and other retinal disorders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Honolulu, Hawaii, United States
Hilo, Hawaii, United States
Kahului, Hawaii, United States
Kailua Kona, Hawaii, United States
Patients applied
Trial Officials
George Papastergiou, MD
Principal Investigator
Retina Institute of Hawaii
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials